At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 129 enrolled
Drug / intervention
pantoprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD.
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Aug 17, 2006·Updated May 4, 2010
In Brief
A Phase 3 clinical trial evaluating pantoprazole and Placebo for Gastroesophageal Reflux. Completed, enrolled 129 participants across 38 sites.
Detailed Summary
To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartSep 2006
Primary CompletionNov 2007
TodayJul 2026
First PostedAug 17, 2006
Enrollment StartSep 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.9 years ago
Interventions
pantoprazoledrug
Placebodrug